Nkarta, Inc.
Industry
- Pharmaceuticals
- Biotechnology
- Gene Therapy, Cell Therapy
Latest on Nkarta, Inc.
An increasingly popular antigen in hematology-oncology as well as solid tumor oncology is CD70, with a number of players developing therapies to target it. But Pfizer believes its PF-08046040, acquire
Cullinan Oncology, Inc. is changing course and increasing its focus on inflammation and immunology. The company will rebrand as Cullinan Therapeutics, Inc. as it moves CLN-978, its CD19xCD3-directed
US initial public offerings by biopharmaceutical companies appear to be on the rise in 2024 with nine during the first quarter, including Boundless Bio Inc. ’s $100m IPO on 27 March, outpacing 2023 w
“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning